Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: peter michaelson who wrote (828)	3/26/2000 10:47:00 PM
From: Bosco	Read Replies (1) \| Respond to of 1298

Hi Peter - I hope so too. Upon reading Exacctnt's post and rereading yours, I realised that both of you were responding to www.geneticcapital.com's post [I didn't read it directly though, since I wasn't about to download a word document from an unknown source!] north 40 was kind enough to make an excerpt. I actually agree with you and Exacctnt. I think the word 'arbitrage' is a strange word to use in this context. Also, IRS is unlikely to allow any tax free treatment even if CEGE chooses to sell the 12% of ABGX stock. So, Exacctnt's point about taxation absolutely to the point. Quite frankly, I don't know why the former wants to do so. As a mental preparation, CEGE investors should make a big discount on this ABGX holding and see if CEGE is still worth it. Personally, I think so. best, Bosco